Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. (Q50719439)

18 March 2018

title

Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. (English)

1 reference

18 March 2018

author name string

Jagpal S Klair

1

1 reference

18 March 2018

Mohit Girotra

2

1 reference

18 March 2018

Laura F Hutchins

3

1 reference

18 March 2018

Kari D Caradine

4

1 reference

18 March 2018

Farshad Aduli

5

1 reference

18 March 2018

Mauricio Garcia-Saenz-de-Sicilia

6

1 reference

18 March 2018

publication date

5 February 2016

1 reference

18 March 2018

Digestive Diseases and Sciences

published in

1 reference

18 March 2018

volume

61

1 reference

18 March 2018

issue

7

1 reference

18 March 2018

page(s)

2132-2139

1 reference

18 March 2018

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Colitis associated with biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Lymphocytic colitis secondary to ipilimumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab-induced perforating colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab-associated colitis: CT findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab-induced acute severe colitis treated by infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

TNF alpha antagonist therapy and safety monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Steroid-induced sigmoid diverticular perforation in a patient with temporal arteritis: a rare clinical pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4042-4

Ipilimumab approved for metastatic melanoma

21 January 2018

1 reference

12 December 2020

Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab

1 reference

12 December 2020

Atypical presentation of colon perforation related to corticosteroid use

1 reference

12 December 2020

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma

1 reference

12 December 2020

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

1 reference

12 December 2020

10.1007/S10620-016-4042-4

Identifiers

DOI

1 reference

18 March 2018

1 reference

18 March 2018